The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / After COVID-19-Associated MIS-C, Immune Changes Resolve

After COVID-19-Associated MIS-C, Immune Changes Resolve

September 1, 2020 • By Marilynn Larkin

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—A new study of multisystem inflammatory syndrome in children (MIS-C) shows that the immune system is profoundly altered during acute illness, but gradually returns back to normal.

You Might Also Like
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • ACR Releases COVID-19 & MIS-C Clinical Guidance for Kids with Rheumatic Disease
  • Unprecedented Cluster of Hyperinflammatory Shock in Kids in U.K., possibly Linked to COVID-19

MIS-C is distinct from both COVID-19 and Kawasaki disease, but is associated with previous SARS-CoV-2 infection, the immunological profiling study reveals.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Manu Shankar-Hari, an NIHR Clinician Scientist at Guy’s and St Thomas’, London, tells Reuters Health by email, “The immune system changes [during treatment] highlight that there is excess inflammation. The treatments that are commonly administered, such as corticosteroid and intravenous immunoglobulins, appear to favorably alter the immune system changes.”

As reported in Nature Medicine, Dr. Shankar-Hari and colleagues performed peripheral leukocyte phenotyping for 25 children (median age: 12.5; 60% boys) with MIS-C, in the acute (23 patients; worst illness within 72 hrs of admission), resolution (14; clinical improvement) and convalescent (10; first outpatient visit) phases.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At baseline, 72% had gastrointestinal symptoms, 28% had radiological evidence of pneumonia, 56% had vasoactive infusions and 28% had coronary artery dilatation or aneurysm. Among those with MIS-C, 17 (68%) were SARS-CoV-2 seropositive, suggesting previous SARS-CoV-2 infections; these children had more severe disease.

Comparing blood samples from affected children at each stage of the disease with samples from age-matched healthy controls, the authors observed high levels of cytokines in the acute phase of MIS-C—e.g., interleukin-1 beta, IL-6, IL-8, IL-10, IL-17, interferon-gamma—as well as T and B cell subset lymphopenia. These immune responses were similar to those observed in adults with COVID-19 infection.

Further, high CD64 expression on neutrophils and monocytes, and high HLA-DR expression on gamma delta and CD4+CCR7+ T cells in the acute phase suggested that these immune cells were also activated.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Low HLA-DR and CD86 expression was observed in antigen-presenting cells, potentially indicating impaired antigen presentation.

By the convalescent phase, these immune cell populations returned to normal. Taken together, the findings suggest that immune responses in MIS-C and adult COVID-19 patients share similarities as well as differences (e.g., in numbers of neutrophils), and that MIS-C is likely not the same as Kawasaki disease.

“Clinicians should be telling families that MIS-C is a rare illness and children get better with commonly administered treatments,” Dr. Shankar-Hari says. “We do not know why some children are getting this illness. Further research is underway to address that.”

Daphne Hsu, MD, division chief of Pediatric Cardiology at Children’s Hospital at Montefiore in New York City, comments in an email to Reuters Health, “The observations … support the general consensus that MIS-C is an immunologically mediated disease. The fact the abnormalities were most prominent in the acute phase and had for the most part completely resolved by the convalescent phase support clinical observations that MIS-C is a self-limited disease in the vast majority of patients.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Children, COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C)

You Might Also Like:
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • ACR Releases COVID-19 & MIS-C Clinical Guidance for Kids with Rheumatic Disease
  • Unprecedented Cluster of Hyperinflammatory Shock in Kids in U.K., possibly Linked to COVID-19
  • Doctors Detail Kawasaki-Like Disease in Adult COVID-19 Patients

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)